Synlogic Inc. (NASDAQ: SYBX)
$1.56
+0.0600 ( +4.00% ) 12.9K
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.
Market Data
Open
$1.56
Previous close
$1.50
Volume
12.9K
Market cap
$18.26M
Day range
$1.52 - $1.63
52 week range
$1.35 - $8.85
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 13 | May 14, 2024 |
10-q | Quarterly Reports | 72 | May 14, 2024 |
10-k/a | Quarterly Reports | 13 | Apr 29, 2024 |
4 | Insider transactions | 1 | Apr 04, 2024 |
4 | Insider transactions | 1 | Apr 04, 2024 |
4 | Insider transactions | 1 | Mar 21, 2024 |
8-k | 8K-related | 11 | Mar 21, 2024 |
3 | Insider transactions | 2 | Mar 21, 2024 |
3 | Insider transactions | 2 | Mar 21, 2024 |
8-k | 8K-related | 13 | Mar 19, 2024 |